US Patent 9,956,205: Lesinurad Crystalline Polymorph Claims, Expiration, Orange Book Status, and Generic Risk
US Patent 9,956,205 protects two crystalline polymorphs of lesinurad, the active ingredient in Zurampic. Its enforceable value is concentrated in solid-state form and treatment-method claims, not in the lesinurad chemical composition itself. The patent issued May 1, 2018, and has an expected expiration date of October 30, 2035, subject to any patent-term adjustment or disclaimer recorded in the official patent file.[1]
The claims cover administration of lesinurad polymorphs identified by specific X-ray powder diffraction, or XRPD, peaks. The patent does not claim every lesinurad crystal form, every lesinurad formulation, or lesinurad as a chemical entity. Generic entry risk therefore depends on the solid form used in the ANDA product, the proposed labeling, and whether the product would be used for the patented gout indication.
What drug and crystalline forms does US Patent 9,956,205 protect?
The patent covers lesinurad, chemically identified as:
2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid.
Lesinurad is a selective uric acid transporter 1 inhibitor. The FDA approved it under the brand name Zurampic as an adjunct to a xanthine oxidase inhibitor, such as allopurinol or febuxostat, for hyperuricemia associated with gout.[2]
The patent claims two solid forms:
| Patent claim group |
Defining XRPD peaks |
Additional limitations |
| Claims 1-6 |
10.46, 18.76 and 19.83° 2θ ±0.1° |
Optional peaks at 18.21 or 23.08°; FIG. 5 pattern; water/ethyl acetate crystallization; combination with allopurinol or febuxostat |
| Claims 7-12 |
10.32, 18.84 and 20.75° 2θ ±0.1° |
At least two additional peaks from the listed set; FIG. 1 pattern; water/acetic acid crystallization; combination with allopurinol or febuxostat |
The claim structure indicates that the patent distinguishes at least two lesinurad polymorphs based on their diffraction signatures. The precise polymorph names, such as Form I or Form II, should not be inferred solely from the claim text unless confirmed by the specification and prosecution history.
How broad are the independent claims in US 9,956,205?
Claims 1 and 7 are method-of-treatment claims. Each requires four principal elements:
- Treatment of hyperuricemia associated with gout.
- Administration of an effective amount of lesinurad.
- Use of a specified crystalline polymorph.
- Identification of that polymorph through required XRPD peaks.
The claims do not require that the patient previously failed allopurinol or febuxostat. Claims 5, 6, 11 and 12 separately add co-administration with allopurinol or febuxostat.
The independent claims are narrower than a claim to lesinurad generally. A product could contain lesinurad yet avoid literal infringement if it uses a different crystalline form that does not satisfy the required XRPD limitations. That distinction is central to generic design-around analysis.
What do the XRPD limitations require?
The peak limitations are quantitative identity limitations. A polymorph must exhibit the specified peaks within ±0.1° 2θ. The dependent claims add either additional peak requirements or a pattern substantially the same as the patent figures.
The principal claim-construction issues are likely to include:
- Whether each listed peak must be present in the accused material.
- How peak position, intensity and analytical tolerance are measured.
- The meaning of “substantially the same” XRPD pattern.
- Whether mixtures of polymorphs fall within the claims.
- Whether manufacturing or storage conditions convert one lesinurad form into another.
- Whether the claimed peaks distinguish a discrete polymorph or overlap with a partially crystalline mixture.
A generic manufacturer would normally characterize the final active pharmaceutical ingredient, formulation and stability samples by XRPD. Solid-form conversion during milling, granulation, compression, storage or dissolution could create additional infringement exposure even if the initial API was manufactured as a different form.
What do claims 4 and 10 add regarding manufacturing?
Claims 4 and 10 add crystallization process limitations:
- Claim 4 requires crystallization from a mixture of water and ethyl acetate.
- Claim 10 requires crystallization from a mixture of water and acetic acid.
These are dependent method-of-treatment claims, not standalone manufacturing claims. The claims therefore do not directly prohibit all manufacture of a polymorph using those solvents. They require administration of the resulting polymorph and incorporate the specified crystallization step into the claimed treatment method.
This structure makes claims 4 and 10 narrower and potentially harder to assert against a generic manufacturer unless the manufacturing route is discoverable and matches the claimed solvent system. The broader enforcement value remains in claims 1 and 7, which do not require the accused manufacturer to use the listed crystallization process.
What do the allopurinol and febuxostat combination claims protect?
Claims 5, 6, 11 and 12 cover administration of the claimed lesinurad polymorph with either:
- Allopurinol; or
- Febuxostat.
These claims align with Zurampic’s FDA-approved use as add-on therapy to a xanthine oxidase inhibitor. They could become relevant where a generic label expressly instructs concurrent use with allopurinol or febuxostat.
The combination claims are narrower than the independent polymorph claims because they require proof of co-administration. They may still have practical value if the FDA-approved indication and prescribing information encourage use with those agents. A generic applicant seeking a Section viii carve-out would need to remove patented methods from labeling where FDA rules permit such a carve-out. Whether a carve-out is available depends on the scope of the listed use code and the remaining non-patented indications.
When does US Patent 9,956,205 expire?
| Event |
Date |
| Earliest priority date reported for the family |
October 31, 2014 |
| International or nonprovisional filing period |
October 30, 2015 |
| US patent issuance |
May 1, 2018 |
| Expected ordinary expiration |
October 30, 2035 |
| Patent term adjustment |
Must be confirmed from the USPTO patent record |
| Patent term extension under 35 U.S.C. §156 |
No confirmed extension identified for this patent |
The expected expiration is based on the 20-year term calculated from the relevant nonprovisional filing date. A provisional filing does not begin the 20-year patent term. Any patent-term adjustment shown on the front page or USPTO maintenance record could move the effective expiration date.[1]
The patent issued after FDA approval of Zurampic, which occurred on December 22, 2015. FDA approval did not create a biologic exclusivity period because lesinurad is a small-molecule drug.[2]
What is the FDA and Orange Book status of Zurampic?
Zurampic was approved by FDA as an oral lesinurad product for use with an xanthine oxidase inhibitor in patients with gout-associated hyperuricemia.[2] The approved labeling did not authorize lesinurad monotherapy because of renal safety concerns.
Key FDA facts include:
| Regulatory item |
Status |
| Active ingredient |
Lesinurad |
| Brand |
Zurampic |
| Sponsor at approval |
AstraZeneca |
| FDA approval date |
December 22, 2015 |
| Dosage form |
Oral tablet |
| Approved use |
Adjunct to allopurinol or febuxostat |
| Regulatory pathway |
NDA, small molecule |
| Biosimilar pathway |
Not applicable |
| Generic pathway |
ANDA under Hatch-Waxman |
| Market status |
US commercial availability was discontinued after limited commercial uptake |
FDA’s Orange Book status must be separated from the patent’s technical scope. Orange Book listing provides notice for ANDA applicants and supports patent-certification procedures, but it does not expand claims beyond their actual language. The relevant listed patent, if active in the applicable Orange Book edition, would expose an ANDA applicant to a Paragraph IV certification and possible litigation under 35 U.S.C. §271(e)(2).
Are there Paragraph IV challenges to US 9,956,205?
A Paragraph IV challenge would assert that the patent is invalid, unenforceable or not infringed. For this patent, the most likely technical grounds would involve:
- A different lesinurad polymorph.
- Failure of the proposed product to exhibit the claimed XRPD peaks.
- Lack of infringement because the label omits the patented gout-treatment use.
- Anticipation or obviousness based on earlier lesinurad solid-form disclosures.
- Insufficient written description or enablement for the claimed polymorph definitions.
- Indefiniteness involving “substantially the same” XRPD patterns.
- Non-infringement of the solvent-specific dependent claims.
The patent’s method format creates a significant Hatch-Waxman issue. An ANDA applicant can seek approval for a label that omits a patented method, but that strategy does not eliminate risk if the remaining label still induces use of the claimed polymorph for hyperuricemia associated with gout.
No major public patent-litigation campaign involving US 9,956,205 is identified in the materials supplied with the claim set. The existence of a Paragraph IV notice, settlement agreement or district-court action must be determined from the Orange Book, FDA Paragraph IV notice records and PACER litigation filings.
How strong is the patent estate for lesinurad?
US 9,956,205 is a focused solid-state patent. Its strength is strongest where the commercial product uses one of the claimed polymorphs and the product label covers the claimed gout indication.
| Risk factor |
Assessment |
| Chemical composition protection |
Not provided by the quoted claims |
| Polymorph protection |
Strong for the two XRPD-defined forms |
| Formulation protection |
Not provided by the quoted claims |
| Method-of-use protection |
Present and tied to gout-associated hyperuricemia |
| Combination protection |
Present for allopurinol and febuxostat |
| Manufacturing protection |
Limited; solvent steps appear only in dependent treatment claims |
| Small-molecule generic exposure |
Material if the generic uses a claimed form |
| Biosimilar exposure |
None |
| Design-around potential |
Meaningful if a stable, non-infringing form can be developed |
| Analytical enforceability |
Dependent on XRPD testing and form stability |
The patent does not, on the supplied claims, cover tablets, excipients, dissolution profiles, particle size, salt forms, dosage strengths, packaging or a general method of lowering serum urate. Separate patents would be needed for those features.
Which companies challenge or compete with lesinurad?
Lesinurad competes pharmacologically with established urate-lowering therapies:
| Product |
Active ingredient |
Mechanism or role |
Generic or biosimilar status |
| Zurampic |
Lesinurad |
URAT1 inhibitor used with a xanthine oxidase inhibitor |
Small-molecule generic pathway |
| Zyloprim and generics |
Allopurinol |
Xanthine oxidase inhibitor |
Generic competition established |
| Uloric and generics |
Febuxostat |
Xanthine oxidase inhibitor |
Generic competition established |
| Krystexxa |
Pegloticase |
Enzyme replacement therapy |
Biologic; biosimilar considerations differ |
| Benemid and generics |
Probenecid |
Uricosuric therapy |
Generic competition established |
Lesinurad’s commercial position was weakened by the requirement for combination use, renal safety monitoring and competition from low-cost allopurinol and febuxostat. AstraZeneca discontinued US commercial availability after limited uptake, reducing current revenue exposure relative to the period immediately after launch.[3]
What generic launch scenarios exist for Zurampic?
Three launch scenarios are commercially relevant.
At-risk launch before October 2035
A generic applicant could file an ANDA with a Paragraph IV certification and launch before patent expiration if it prevails in litigation or reaches a settlement permitting launch. The principal litigation question would be whether the API or finished product contains a claimed polymorph.
Delayed launch after a successful design-around
A manufacturer could develop a non-infringing crystalline form and support it with XRPD, thermal analysis and stability data. This route would reduce infringement risk but would require regulatory support showing that the alternative form is pharmaceutically equivalent and does not create unacceptable manufacturing or bioavailability differences.
Label carve-out
A generic applicant could attempt to remove patented combination-use language. This strategy is less useful if the only commercially meaningful use is the patented adjunctive gout indication. FDA labeling, use codes and actual prescribing behavior would control practical exposure.
Because the product was commercially discontinued, the incentive to file an ANDA may be lower than for a high-revenue branded drug. Low current sales do not eliminate patent risk, but they reduce the expected value of an expensive polymorph challenge.
What licensing deals affect the lesinurad patent landscape?
AstraZeneca acquired Ardea Biosciences in 2012 and obtained control of Ardea’s lesinurad program and related intellectual property.[4] That transaction consolidated ownership of the lesinurad patent estate under AstraZeneca. The relevant commercial rights and licensing arrangements should be distinguished from patent ownership: a company may commercialize or distribute a product without owning the underlying patent.
The supplied patent claims identify the patent holder and inventorship through the official patent record, but they do not establish a separate license grant, covenant not to sue or generic settlement. No such agreement can be inferred from the claims alone.
Key Takeaways
- US Patent 9,956,205 is a lesinurad crystalline-polymorph patent.
- Claims 1 and 7 cover treatment of gout-associated hyperuricemia using two XRPD-defined polymorphs.
- Claims 5, 6, 11 and 12 cover combination use with allopurinol or febuxostat.
- Claims 4 and 10 add water/ethyl acetate and water/acetic acid crystallization limitations.
- The expected patent expiration is October 30, 2035, subject to USPTO-recorded term adjustments.
- The patent does not, based on the supplied claims, cover the lesinurad molecule broadly, tablets generally or every lesinurad solid form.
- Generic risk is highest when the proposed product contains either claimed polymorph and carries the approved gout-treatment labeling.
- Lesinurad is a small molecule, so biosimilar competition is not applicable.
- The commercial incentive for a Paragraph IV challenge is reduced by Zurampic’s limited US commercial performance and discontinuation.
FAQs
Does US Patent 9,956,205 cover lesinurad monotherapy?
No. The quoted claims require treatment of hyperuricemia associated with gout using a specified lesinurad crystalline polymorph. Claims 5, 6, 11 and 12 specifically require combination with allopurinol or febuxostat, consistent with Zurampic’s adjunctive FDA label.
Can a generic use a different lesinurad polymorph?
Potentially. A different polymorph may avoid literal infringement if it does not meet the claimed XRPD peak limitations. The generic manufacturer would need analytical data demonstrating that the product does not convert into a claimed form during manufacturing, storage or use.
Is US Patent 9,956,205 a formulation patent?
No. The quoted claims are directed to crystalline forms and treatment methods. They do not recite tablet excipients, coatings, dissolution characteristics, dosage strengths or a specific finished dosage-form composition.
Does the patent protect crystallization using water and ethyl acetate?
Only in the narrow context of dependent claim 4. The quoted claim does not independently prohibit manufacturing with water and ethyl acetate. It requires administration of the resulting polymorph in the claimed treatment method.
Is a biosimilar filing available for Zurampic?
No. Lesinurad is a small-molecule active ingredient regulated through the NDA/ANDA framework. A competing manufacturer would pursue a generic drug application rather than a biosimilar application.
References
- United States Patent and Trademark Office. (2018). U.S. Patent No. 9,956,205, Crystalline forms of lesinurad.
- U.S. Food and Drug Administration. (2015). Zurampic (lesinurad) prescribing information and approval materials.
- AstraZeneca PLC. (2019). Annual report and product portfolio disclosures.
- AstraZeneca PLC. (2012). Acquisition of Ardea Biosciences and lesinurad program materials.